Exposure to Toxins in Children Associated with Kidney Disease Biomarker
|
By LabMedica International staff writers Posted on 26 Jul 2016 |

Image: New research shows children living in Mexico who are exposed to multiple toxins evidence a higher incidence of chronic kidney disease (Photo courtesy of BWH).
Researchers have assessed environmental exposure to multiple toxins in children living in a region of Mexico with a high incidence of chronic kidney disease, especially among young adults. They not only detected high levels of arsenic and chromium in urine samples, they also detected elevated levels of Kidney Injury Molecule-1 (KIM-1), a biomarker currently being studied as an early sign of kidney injury.
Exposure to environmental toxins – such as arsenic, cadmium, chromium, lead, and other heavy metals – early in life via contaminated water or other sources often have long-term health consequences as children grow. Investigators at Brigham and Women's Hospital (BWH; Boston, MA, USA) and Harvard Medical School (Boston, MA, USA) have found exceedingly high levels of arsenic and chromium in urine samples collected from 107 children living in the north-central region of Mexico – levels that were even higher than exposure limits set for adults. When the team measured traditional biomarkers of kidney function – such as those measured at a routine physical exam – they did not find elevated levels of these markers. However, more sensitive and specific biomarkers of kidney injury recently qualified by the FDA for use in preclinical studies, e.g. KIM-1, were elevated in the children. KIM-1 might serve as a sensitive biomarker to screen children for kidney damage induced by environmental toxic agents.
“Until now, no one has studied these children – an especially vulnerable population – to determine their risk of exposure and possible measures of kidney dysfunction,” said senior author Vishal Vaidya, PhD, of BWH and Harvard, “KIM-1 may be an early warning sign of exposure, suggesting that something may be beginning to go wrong in the epithelial cells in the kidneys of these children. Many questions remain to be answered. We don’t know if this effect might be reversible, we don’t know if there are other kidney toxic contaminants such as uranium present as well. Because we don’t have follow-up data from these children we also don’t know the long-term consequences of this exposure. But this does give us our first insights into this population at a young age.”
“For the first time, we’ve been able to evaluate and assess an early warning sign of kidney injury – one that may give us the ability to act in advance before there is irreversible harm,” said first author Mariana Cardenas-Gonzalez, PhD, postdoctoral fellow in the Vaidya lab, “This may be a problem that can be solved by reducing exposure, but first we need to understand how such high levels of these toxins are winding up in the urine of these children.”
The research team also tested water samples from the children’s tap water, identifying contaminated drinking supply as the likely source of arsenic. The source of chromium, however, remains unknown so further investigation is needed. Chromium exposure can come from contaminated air, soil, water, food, or tobacco products.
The study, by Cardenas-Gonzalez M et al, was published online July 15, 2016, in the journal Environmental Research.
Related Links:
Brigham and Women's Hospital
Harvard Medical School
Exposure to environmental toxins – such as arsenic, cadmium, chromium, lead, and other heavy metals – early in life via contaminated water or other sources often have long-term health consequences as children grow. Investigators at Brigham and Women's Hospital (BWH; Boston, MA, USA) and Harvard Medical School (Boston, MA, USA) have found exceedingly high levels of arsenic and chromium in urine samples collected from 107 children living in the north-central region of Mexico – levels that were even higher than exposure limits set for adults. When the team measured traditional biomarkers of kidney function – such as those measured at a routine physical exam – they did not find elevated levels of these markers. However, more sensitive and specific biomarkers of kidney injury recently qualified by the FDA for use in preclinical studies, e.g. KIM-1, were elevated in the children. KIM-1 might serve as a sensitive biomarker to screen children for kidney damage induced by environmental toxic agents.
“Until now, no one has studied these children – an especially vulnerable population – to determine their risk of exposure and possible measures of kidney dysfunction,” said senior author Vishal Vaidya, PhD, of BWH and Harvard, “KIM-1 may be an early warning sign of exposure, suggesting that something may be beginning to go wrong in the epithelial cells in the kidneys of these children. Many questions remain to be answered. We don’t know if this effect might be reversible, we don’t know if there are other kidney toxic contaminants such as uranium present as well. Because we don’t have follow-up data from these children we also don’t know the long-term consequences of this exposure. But this does give us our first insights into this population at a young age.”
“For the first time, we’ve been able to evaluate and assess an early warning sign of kidney injury – one that may give us the ability to act in advance before there is irreversible harm,” said first author Mariana Cardenas-Gonzalez, PhD, postdoctoral fellow in the Vaidya lab, “This may be a problem that can be solved by reducing exposure, but first we need to understand how such high levels of these toxins are winding up in the urine of these children.”
The research team also tested water samples from the children’s tap water, identifying contaminated drinking supply as the likely source of arsenic. The source of chromium, however, remains unknown so further investigation is needed. Chromium exposure can come from contaminated air, soil, water, food, or tobacco products.
The study, by Cardenas-Gonzalez M et al, was published online July 15, 2016, in the journal Environmental Research.
Related Links:
Brigham and Women's Hospital
Harvard Medical School
Latest Molecular Diagnostics News
- Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
- Liquid Biopsy Biomarkers Distinguish Inflammatory Breast Cancer and Support Monitoring
- Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
- Whole-Blood RNA Test Predicts Disease Trajectory and Treatment Response
- Blood-Based Epigenetic Test Predicts GLP-1 Response and Tracks Treatment Effects
- Tumor Genomic Testing Guides Immunotherapy Selection in Pituitary Tumors
- Liquid Biopsy Predicts Immunotherapy Response in Breast Cancer
- New Blood Test Distinguishes Pancreatic Cancer From Benign Disease
- Noninvasive Test Confirms High-Risk Prenatal Screening Results from Blood
- Machine-Learning Genetic Risk Score Improves Early Prediction of Type 1 Diabetes
- Rapid Tongue Swab Molecular Test Detects Pulmonary Tuberculosis at Point of Care
- CRISPR-Based Test Identifies Multiple Respiratory Viruses Simultaneously
- Blood Test Receives FDA Breakthrough Status to Differentiate Schizophrenia and Bipolar Disorder
- Portable Test Detects Tuberculosis from Tongue Swabs in 30 Minutes
- Multi-Omic Assay Predicts Recurrence and Radiation Benefit in Early Breast Cancer
- Genomic Risk Score Identifies Inherited Risk for Multiple Cardiovascular Conditions
Channels
Clinical Chemistry
view channel
Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read more
Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
High blood pressure during pregnancy is common and can progress to pre-eclampsia, making close monitoring at antenatal visits essential. However, most risk assessment begins only after pregnancy has started.... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreImmunology
view channel
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more
T-Cell Senescence Profiling May Predict CAR T Responses
Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more
New Platform Captures Extracellular Vesicles for Early Cancer Detection
Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more








